BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

Castle Biosciences

Castle Biosciences

CSTL

0.00

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ: CSTL) with a Buy and raises the price target from $40 to $44.